Quantitative comparison of the cross-protection induced by tick-borne encephalitis virus vaccines based on European and Far Eastern virus subtypes.

Authors:
Address: Baxter BioScience, Vaccine Research and Development, Biomedical Research Centre, Uferstrasse 15, A-2304 Orth a.d. Donau, Austria.
Journal:

Publication:

abstract

tick-borne encephalitis virus (TBEV) is a flavivirus of wide geographic distribution and the causative agent of tick-borne encephalitis (TBE), an infection of the central nervous system. TBE has the highest incidence rate in Russia, where locally produced as well as Western European vaccines for the prevention of TBE are available. The Western European vaccines are based on TBE viruses that belong to the European subtype, while the Russian vaccines are based on Far Eastern subtype viruses. The question of to which extent vaccination with a vaccine based on the European subtype is effective in protecting against the heterologous Far Eastern virus subtype - and vice versa - has not been answered conclusively. Here we immunized mice with TBE vaccines based on European and Far Eastern subtype viruses, and used an unbiased hybrid virus test system to determine cross-neutralizing antibody titers and cross-protective efficacy. All vaccines tested elicited cross-protective responses against the heterologous strains, similar to those induced against the respective homologous vaccine strains. These data, therefore, fully support the use of TBE vaccines in geographic regions where virus subtypes heterologous to the vaccine strains are prevalent.

Related Articles
A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans.
J Infect Dis. 2011
A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans.
Orlinger KK, Hofmeister Y, Fritz R, Holzer GW, Falkner FG, Unger B, Loew-Baselli A, Poellabauer EM, Ehrlich HJ, Barrett PN, et al. J Infect Dis. 2011 Jun 1; 203(11):1556-64.
Evaluation of European tick-borne encephalitis virus vaccine against recent Siberian and far-eastern subtype strains.
Vaccine. 2001
Evaluation of European tick-borne encephalitis virus vaccine against recent Siberian and far-eastern subtype strains.
Hayasaka D, Goto A, Yoshii K, Mizutani T, Kariwa H, Takashima I. Vaccine. 2001 Sep 14; 19(32):4774-9.
Evaluation of tick-borne encephalitis DNA vaccines in monkeys.
Virology. 1999
Evaluation of tick-borne encephalitis DNA vaccines in monkeys.
Schmaljohn C, Custer D, VanderZanden L, Spik K, Rossi C, Bray M. Virology. 1999 Oct 10; 263(1):166-74.
Review The current perspective on tick-borne encephalitis awareness and prevention in six Central and Eastern European countries: report from a meeting of experts convened to discuss TBE in their region.
Vaccine. 2011
Review The current perspective on tick-borne encephalitis awareness and prevention in six Central and Eastern European countries: report from a meeting of experts convened to discuss TBE in their region.
Kollaritsch H, Chmelík V, Dontsenko I, Grzeszczuk A, Kondrusik M, Usonis V, Lakos A. Vaccine. 2011 Jun 20; 29(28):4556-64. Epub 2011 May 5.
Review [Monitoring of tick-borne encephalitis virus populations and etiological structure of morbidity over 60 years].
Vopr Virusol. 2005
Review [Monitoring of tick-borne encephalitis virus populations and etiological structure of morbidity over 60 years].
Pogodina VV. Vopr Virusol. 2005 May-Jun; 50(3):7-13.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.